Summit Therapeutics to Participate in February Investor Conferences

Summit Therapeutics plc

("Summit", the "Company", or the "Group")


Oxford, UK, 2 February 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York City in February.


  • Canaccord Genuity Rare Disease and BioPharma One-on-One Day - February 7, 2017
  • BIO CEO & Investor Conference - February 13, 2017; presentation at 10:30am EST
  • SunTrust Robinson Humphrey Orphan Drug Day - February 14, 2017


For the Canaccord Genuity and SunTrust Robinson Humphrey events, the Company will participate in one on one meetings. A live audio webcast of the BIO CEO & Investor Conference presentation will be available through the Investors section on the Company's website, . A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office)


Tel: +44 (0)1235 443 951

  +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)

Liam Murray / Tony Rawlinson



Tel: +44 (0)20 7213 0880
N+1 Singer


Aubrey Powell / Jen Boorer 



Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications

(US media contact)

Chris Erdman / Karen Sharma


Tel: +1 781 235 3060
Consilium Strategic Communications
(Financial public relations, UK)

Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire